

This article was downloaded by:

On: 14 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## **Molecular Simulation**

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713644482>

### **Structural and electronic features of the ubiquinone and ubiquinol molecules: molecular dynamics and quantum chemical treatments**

E. D. Tekin<sup>a</sup>; S. Erkoç<sup>a</sup>

<sup>a</sup> Department of Physics, Middle East Technical University, Ankara, Turkey

Online publication date: 15 October 2010

**To cite this Article** Tekin, E. D. and Erkoç, S.(2010) 'Structural and electronic features of the ubiquinone and ubiquinol molecules: molecular dynamics and quantum chemical treatments', *Molecular Simulation*, 36: 10, 763 — 771

**To link to this Article:** DOI: 10.1080/08927021003752838

**URL:** <http://dx.doi.org/10.1080/08927021003752838>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## Structural and electronic features of the ubiquinone and ubiquinol molecules: molecular dynamics and quantum chemical treatments

E.D. Tekin and S. Erkoç\*

Department of Physics, Middle East Technical University, Ankara 06531, Turkey

(Received 18 November 2009; final version received 5 March 2010)

The coenzyme Q (CoQ) molecule plays a critical role in the biochemical generation of energy in the form of adenosine triphosphate. Various types of CoQ can be classified according to their number of isoprenoid units in the tail. In human beings, CoQ10 is produced and is necessary for the basic functioning of cells. CoQ10 exists in two forms, as ubiquinone (UQ) and as ubiquinol (UQH<sub>2</sub>), which have different roles in the body. Molecular dynamics (MD) simulations for the analysis of the effects of solvents on the structure of the UQ molecule are presented. Besides, semi-empirical molecular orbital PM3 calculation is applied to obtain structural and electronic properties of both the UQ and the UQH<sub>2</sub> molecules. According to the MD simulation, the UQ molecule seems to be flexible both in vacuum and in water. On the other hand, the molecule stays more rigid in methanol. PM3 calculations show that both molecules are quite hydrophobic. Furthermore, UQ is chemically more reactive than UQH<sub>2</sub>, but the latter is kinetically more stable than the former.

**Keywords:** coenzyme Q10; ubiquinone; ubiquinol; molecular dynamics; PM3

### 1. Introduction

Coenzyme Q (CoQ) is a lipid-soluble vitamin-like compound composed of quinone with a benzene ring and a hydrophobic tail, which is found mostly in mitochondria of all plant and animal cells. Its primary function in cells is producing energy in the form of adenosine triphosphate, which is needed for muscle contraction–relaxation and other basic cellular functions. The various types of CoQ can be classified according to their number of isoprenoid units in the tail. One form of CoQ in human mitochondria is CoQ10, which has 10 isoprenoid units in the tail. In 1957, Crane et al. [1] discovered CoQ10 and, in 1958, characterised its chemical and physical properties [2]. Its chemical structure (2,3-dimethoxy-5 methyl-6-decaprenyl benzoquinone) was reported by Wolf et al. [3]. It is known that natural production of CoQ10 is reduced in several animal species and in human beings with ageing [4,5]. Preliminary works on both animals and human beings show that decreased levels of CoQ10 are found in patients with mitochondrial disorders, congestive heart failure and other cardiovascular diseases, periodontal diseases, hypertension, neurodegenerative diseases such as Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis, cancer, diabetes and HIV/AIDS [6–9]. Having said that, it is not yet clear that the deficiency of CoQ10 causes the above-mentioned diseases. However, some clinical studies show that for various patients, additional intake of CoQ10 gives positive results [10–13].

CoQ10 has two forms: ubiquinone (UQ) and ubiquinol (UQH<sub>2</sub>). UQ (C<sub>59</sub>H<sub>90</sub>O<sub>4</sub>) is the oxidised form of CoQ10

and has a molecular weight of 864 Da. UQH<sub>2</sub> is the reduced form of CoQ10 and has two more hydrogen atoms (C<sub>59</sub>H<sub>92</sub>O<sub>4</sub>) on the head of the molecule, thus has a molecular weight of 866 Da. UQ is vital for energy production. UQH<sub>2</sub> is an active antioxidant [14,15]. When UQ (oxidised form) is ingested and absorbed in the body, 90–95% of the ingested UQ is converted and stored as UQH<sub>2</sub> (reduced form). Yamamoto and Yamashita [16] investigated the ratio of UQH<sub>2</sub> to UQ as a marker of oxidative stress using high-performance liquid chromatography (HPLC) method. They found that, in human plasma, taken from healthy donors, the ratio of UQH<sub>2</sub> to UQ is 95/5. They also observed in patients with any of the diseases, hepatitis, cirrhosis and hepatoma, a significant decrease in UQH<sub>2</sub>. Similar work was carried out by Menke et al. [17]. They developed a HPLC method for the simultaneous detection of UQ and UQH<sub>2</sub> in human plasma. Their study can be of help to explain the function of CoQ10 in the above-mentioned diseases and oxidative damage in neonates and infants. There are many other studies about UQ and UQH<sub>2</sub>, for example, Moncelli et al. [18] investigated the kinetics of UQ reduction to UQH<sub>2</sub> and UQH<sub>2</sub> oxidation to UQ in a self-assembled monolayer of dioleoylphosphatidylcholine. Takahashi et al. [19] studied the distribution of UQ and UQH<sub>2</sub> in rat tissues and subcellular functions. More recent experimental works may be found in [20,21].

There have also been simulations of the UQ molecule. Nilsson et al. [22] have done both classical molecular

\*Corresponding author. Email: erkoc@metu.edu.tr

dynamics (MD) and Car–Parrinello MD simulations of UQ to investigate the potential surface of rotations and the H-bonds around the UQ. Söderhäll and Laaksonen [23] carried out MD simulations of UQ molecule inside a dipalmitoylphosphatidylcholine lipid bilayer, immersed in water. They investigated the effect of the long tail, attached to the quinone ring and lateral diffusion rate. Miyamoto et al. [24] investigated the 3D structure of CoQ10 inclusion complex with  $\gamma$ -cyclodextrin using chemical analyses, nuclear magnetic resonance, HPLC and differential scanning calorimetry and both molecular mechanics (MM) and MD calculations.

Since UQ and UQH<sub>2</sub> are redox pairs, CoQ10 is converted from UQH<sub>2</sub> to UQ and vice versa according to the body's need. However, with age and diseases, the body's ability to make this conversion gets impaired significantly [<http://www.vitafoods.eu.com/page.cfm/action=Seminar/SeminarID=42> (accessed on 21 July 2009); <http://blog.nutri.com/tag/ubiquinol-vs-ubiquinone> (accessed on 21 July 2009)]. UQ is the more common commercially available form, whereas UQH<sub>2</sub> is comparatively new and more expensive to manufacture [<http://www.epic4health.com/idubandubwha.html> (accessed on 21 July 2009); [http://www.alternativehealthjournal.com/article/ubiquinol\\_and\\_ubiquinone\\_what\\_s\\_the\\_difference\\_and\\_why\\_should\\_we\\_care\\_/2740](http://www.alternativehealthjournal.com/article/ubiquinol_and_ubiquinone_what_s_the_difference_and_why_should_we_care_/2740) (accessed on 21 July 2009)].

The purpose of this study is to gain insight into the structure of UQ in vacuum, water and methanol by MD simulations and to obtain the structural and electronic properties of UQ and UQH<sub>2</sub> using quantum chemical methods. The interesting conformations of the molecules under consideration are shown. The main reason for choosing these molecules is their pharmaceutical importance.

## 2. Computational details

In this work, the UQ molecule was investigated using both MD simulations and quantum chemical calculations, whereas the UQH<sub>2</sub> molecule was studied only with quantum chemical calculations.

In the MD simulation case, the initial coordinates of UQ were generated with the help of the HyperChem 7.5 program package (Hypercube, Inc., Gainesville, FL, USA). Figure 1 displays the initial structures of the molecules considered. Then, the obtained structure of UQ was converted to GROMACS [25] topology file by the Dundee PRODRG server [26]. All MD simulations were performed using GROMACS software package with the GROMOS9643A1 force field [27]. Water as a solute was modelled as a simple point charge [28]. The UQ molecule was simulated in vacuum, water and methanol separately. All three systems were considered in a cubic box and a constant number of atoms at fixed pressure and temperature (NPT ensemble) was taken into account. In the simulations, 5389 water molecules and 2700 methanol molecules filled the box. The box size was large enough to accommodate the fully extended molecule. The temperature was kept constant at 310 K using Berendsen thermostat [29] with a coupling time constant of 0.1 ps. The pressure was coupled anisotropically using a Berendsen barostat [29] with a reference pressure of 1 bar in all directions, a coupling constant of 0.2 ps and a compressibility of  $1.12 \times 10^{-6} \text{ bar}^{-1}$ . The linear constraint solver algorithm [30] was applied to constrain all bond lengths. The long-range electrostatic interactions were computed by the particle mesh Ewald method [31] using Fourier grid spacing of 0.12 nm and a cut-off radius of 1.2 nm. The short range, van der Waals, interactions were computed with a shift scheme using a cut-off radius of 1 nm. The neighbour list was updated at every step. The three systems were minimised using a steepest descent algorithm, and then a leap frog algorithm [32] was used to integrate Newton's equations of motion. The Visual MD software program [33] was used for visualisations.

In the second case, namely, quantum chemical calculations, the UQ and the UQH<sub>2</sub> molecules in the gas phase were pre-optimised by applying the MM method [34] using MM+ force field [35]. Then, the structures which were obtained from MM were entirely optimised using semi-empirical self-consistent field




Figure 1. Structures of the UQ (C<sub>59</sub>H<sub>90</sub>O<sub>4</sub>) (upper) and the UQH<sub>2</sub> (C<sub>59</sub>H<sub>92</sub>O<sub>4</sub>) (lower) molecules.




Figure 2. Snapshots of the MD simulations for the UQ molecule in vacuum, water and methanol (solvent molecules in both water and methanol are not shown for clarity).




Figure 3. GROMACS energies for the UQ molecule in (a) vacuum (b) water and (c) methanol.

molecular orbital (SCF-MO) method at PM3 level [36] with the restricted Hartree–Fock [37] formalism. Conjugate gradient method (Polak–Ribiere algorithm) [38] was used to optimise geometries and calculate the electronic structure of the molecules. The SCF convergence limit was set to 0.0001 kcal/mol and the criterion of RMS gradient was set to 0.004 kcal/(Å mol) in the calculations. These calculations were performed using HyperChem 7.5 program package (Hypercube, Inc.).

### 3. Results and discussion

UQ was simulated first in vacuum at 310 K for 6 ns. The same procedure was applied for both water and methanol solvents. A snapshot view for all three cases is displayed in Figure 2. As shown in Figure 2, the geometry of the molecule and its dynamics in water resemble its geometry and dynamics in vacuum. Namely, both in vacuum and water, the molecule seems to be flexible. On the other hand, in methanol, the molecule stays more






Figure 4. Optimised structure of (a) the UQ and (b) the UQH<sub>2</sub> molecules in the gas phase (PM3 results).

rigid. Since it is lipophilic, it folds to minimise its surface to reduce its interaction with water. As shown in Figure 3, the total energy of the molecule in vacuum is positive with a value of 259.647 kJ/mol. In water and methanol, the total energy is negative with values of  $-176,909$  and  $-64737.8$  kJ/mol, respectively. This is to be expected since the molecule is interacting with the solute. To be able to calculate the self energy of UQ molecule in the solvent, one should calculate also the pure solvent energy and subtract it from the total energy of the whole system (UQ + solvent).

In Figure 4, the optimised geometries of the UQ and UQH<sub>2</sub> molecules as a result of PM3 calculation are shown.




Figure 5. Distribution of the bond lengths (no. of bonds in arbitrary units vs. bond lengths) of the UQ molecule in vacuum (MD result). See text for association of each distribution maxima with the corresponding type of bond.

Although the tails of the two molecules are the same, there are some differences on the head groups of the molecules. Bond lengths of the neighbouring atoms in the tails of both of the molecules are the same that is carbon–carbon single bonds (C–C) are 1.5 Å, carbon–carbon double bonds (C=C) are 1.3 Å and carbon–hydrogen bond (C–H) bonds are 1.1 Å. On the other hand, on the head of the molecules, there are slight differences in the bond lengths of the C–C and C=C bonds, which are not that significant. Also, in the UQ molecule, carbon–oxygen double bonds (C=O) are 1.2 Å but in the UQH<sub>2</sub> molecule instead of these bonds, there are oxygen–hydrogen bonds (O–H), which are 1.0 Å. In both molecules, the carbon–oxygen single bonds (C–O) have the same value of 1.4 Å. Distribution of the bond lengths after MD simulations for the UQ molecule in vacuum is shown in Figure 5. Bond length distributions of the UQ molecule in water and methanol are the same as in the vacuum case, therefore they are not shown separately.

In the quantum chemical treatment, the atomic excess charges are calculated through the Mulliken model, the total

Table 1. Some of the calculated energy values (in kcal/mol) of the UQ and the UQH<sub>2</sub> molecules (MM results with MM+ force field).

Energy component values	UQ	UQH <sub>2</sub>
Bond	3.907	4.160
Angle	17.192	14.483
Dihedral	6.022	7.733
van der Waals	29.914	27.720
Stretch–bend	0.832	0.535
Electrostatic	0.464	2.689
Total energy	58.331	41.850

Table 2. Some of the calculated energy values (in kcal/mol otherwise stated) and dipole moment (in Debye) of the UQ and the UQH<sub>2</sub> molecules (PM3 results).

Quantity	UQ	UQH <sub>2</sub>
Total energy	−220,331.389	−221,070.749
Binding energy	−15,169.0176	−15,305.425
Isolated atomic energy	−205,162.371	−205,765.324
Electronic energy	−2,377,465.423	−2,398,346.357
Core–core interaction	2,157,134.035	2,177,275.608
Heat of formation	−159.092	−191.295
HOMO (eV)	−9.315	−8.642
LUMO (eV)	−1.398	−0.064
HOMO–LUMO gap (eV)	7.917	8.578
Dipole moment	2.425	4.827

charge of each molecule is zero. We note that the atomic charges considered in MD simulations are not exactly the same as in the quantum case. GROMACS considers united atom model, whereas HyperChem provides charge for every atom. These different charge definitions in two different methods of calculations do not affect our results. In the UQ molecule, there are only four positively charged carbon (C) atoms. Two of these with 0.05|*e*| charge are at the outer edge of the molecule and make single bonds with the oxygen (O) atoms. The other two with charges 0.33|*e*| and 0.34|*e*| make double bonds with the O atoms. The charge of the remaining C atoms ranges from −0.03|*e*| to −0.16|*e*|. All the O atoms are always negatively charged with a magnitude of either −0.18|*e*| or −0.27|*e*|. All the hydrogen (H) atoms are positively charged with values in the interval 0.03|*e*|/0.11|*e*|. In the case of the UQH<sub>2</sub> molecule, all the C atoms that make bonds




Figure 6. MO eigenvalues of (a) the UQ and (b) the UQH<sub>2</sub> molecules (PM3 results).

with the O atoms are positively charged with values in between 0.03|*e*| and 0.07|*e*|. The charge of the remaining C atoms ranges from −0.02|*e*| to −0.16|*e*|. All O atoms have a negative charge of −0.18|*e*| or −0.22|*e*|. All H atoms have positive charges in the 0.03|*e*| to 0.20|*e*| interval. There is a large negative charge accumulation on the O atoms.

In Table 1, the values of the energy components obtained by MM with MM+ force field are shown. In both molecules, the largest contribution to the total energy comes from the van der Waals interactions (29.914 kcal/mol for UQ and 27.720 kcal/mol for UQH<sub>2</sub>). The electrostatic interactions have the smallest contribution (0464) for UQ, while the stretch–bend interactions (0535) are smallest for UQH<sub>2</sub>.

In Table 2, the calculated energy values obtained from the PM3 method are given and the MO eigenvalue spectra are shown in Figure 6. The binding energies of both molecules are nearly the same with a value of −15,169 kcal/mol. Both molecules UQ and UQH<sub>2</sub> are




Figure 7. Three-dimensional HOMO and LUMO plots of the UQ molecule (PM3 results).




Figure 8. Three-dimensional HOMO and LUMO plots of the UQH<sub>2</sub> molecule (PM3 results).

exothermic with heat of formation of about  $-159$  and  $-191$  kcal/mol, respectively.

The dipole moments of the UQ and UQH<sub>2</sub> molecules are 2.4 and 4.8 Debyes, respectively. With the same method, the dipole moment of water is calculated to be 1.7 Debye, which means that both the molecules are more polar compared to water. Furthermore, the dipole moment of UQH<sub>2</sub> is larger than the dipole moment of UQ, which means that the UQH<sub>2</sub> molecule is more water soluble compared to UQ as is also known [39]. MD simulation predicted the average dipole moment of the UQ molecule to be about 2.5 Debyes in all three cases, namely in vacuum, water and methanol. MD prediction is consistent with the PM3 result.

According to the PM3 calculation, the gap between the highest occupied molecular orbital (HOMO) and lowest unoccupied molecular orbital (LUMO) energies found for UQ is 7.9 eV and for UQH<sub>2</sub> is 8.6 eV. This implies

that UQH<sub>2</sub> is kinetically more stable than UQ. Conversely, UQ is chemically more reactive than UQH<sub>2</sub>. The present finding is consistent with the recent experimental work on these molecules [40]. Three-dimensional plots of HOMO and LUMO for UQ and UQH<sub>2</sub> are presented in Figures 7 and 8, respectively. In the UQ molecule, the HOMO is mainly localised on the middle part of the tail, while LUMO is mainly localised on the head and the double-bonded oxygen atoms. However, in the UQH<sub>2</sub> molecule, both HOMO and LUMO are localised on the head part only. In Figure 9, 3D electrostatic potential (ESP) plots on UQ and UQH<sub>2</sub> molecules are shown. In both molecules, while negative ESP is mainly localised on the oxygen atoms at the head and on the carbon atoms at the tail, positive ESP is localised on the rest of the molecules. In Figure 10, 3D charge density plots of the UQ and UQH<sub>2</sub> molecules are displayed. Both plots show a uniform distribution.

Additional information can be obtained from  $\log P$ . The calculated  $\log P$  value of the UQ molecule is 14.72,




Figure 9. Three-dimensional ESP plots of (a) the UQ and (b) the UQH<sub>2</sub> molecules (PM3 results).




Figure 10. Three-dimensional charge density plots of (a) the UQ and (b) the UQH<sub>2</sub> molecules (PM3 results).



while that of the UQH<sub>2</sub> molecule is 12.26. These values indicate that the molecules considered are quite hydrophobic. HyperChem calculates the log *P* values from atomic parameters. Actually, UQ is more hydrophobic than UQH<sub>2</sub> molecule, which means that UQH<sub>2</sub> is slightly more water soluble than UQ. The difference in log *P* values of both molecules might be due to the mass difference in their head part, because the two added hydrogen atoms increase the mass of the polar head of the UQH<sub>2</sub> molecule. This analysis confirms the dipole moment calculation.

#### 4. Conclusion

In this study, MD simulations for the analysis of the effects of solvents on the structure of the UQ molecule are presented. Furthermore, semi-empirical MO PM3 calculation is applied to obtain structural and electronic properties of both the UQ and the UQH<sub>2</sub> molecules. The results of the MD simulations show that UQ seems to be flexible both in vacuum and in water and stays more rigid in methanol. The results of the PM3 calculation are compatible with the experiments. Namely, UQ is chemically more reactive than UQH<sub>2</sub>, in addition, the simulation suggests that the latter is kinetically more stable than the former. Both molecules are quite hydrophobic.

#### Acknowledgements

The authors would like to thank the Middle East Technical University (METU) for partial support through the project (METU-BAP-08-11-DPT-2002-K120-510) and Roland Faller's group at UC Davis for access to their computers.

#### References

- [1] F.L. Crane, Y. Hatefi, R.I. Lester, and C. Widmer, *Isolation of a quinone from beef heart mitochondria*, Biochimica et Biophys. Acta 25 (1957), pp. 220–221.
- [2] R.L. Lester, F.L. Crane, and Y. Hatefi, *Coenzyme Q: A new group of quinone*, J. Am. Chem. Soc. 80 (1958), pp. 4751–4752.
- [3] D.E. Wolf, C.H. Hoffman, N.R. Trenner, B.H. Arison, C.H. Shunk, B.O. Linn, J.F. McPherson, and K. Folkers, *Structure studies on the coenzyme Q group*, J. Am. Chem. Soc. 80 (1958), p. 4752.
- [4] R.E. Beyer, B.A. Burnett, K.J. Cartwright, D.E. Edington, M.J. Falzon, K.R. Kreitman, T.W. Kuhn, B.J. Ramp, S.Y. Rhee, and M.J. Rosenwasser, *Tissue coenzyme Q (UQ) and protein concentrations over the life span of the laboratory rat*, Mech. Aging Dev. 32 (1985), pp. 267–281.
- [5] A. Kalen, E.L. Appelkvist, and G. Daliner, *Age-related changes in the lipid compositions of rat and human tissues*, Lipids 24 (1989), pp. 579–584.
- [6] I.L. Hansen, *Bioenergetics in clinical medicine. Gingival leucocytic deficiencies of coenzyme Q10 in patients with periodontal disease*, Res. Comm. Chem. Pathol. Pharmacol. 174 (1976), pp. 729–738.
- [7] K. Folkers, P.H. Langsjoen, Y. Nara, K. Muratsu, J. Komorowski, P.C. Richardson, and T.H. Smith, *Biochemical deficiencies of coenzyme Q10 in HIV-infection and the exploratory treatment*, Biochem. Biophys. Res. Commun. 153 (1988), pp. 888–896.
- [8] K. Lockwood, S. Moesgaard, and K. Folkers, *Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10*, Biochem. Biophys. Res. Commun. 199 (1994), pp. 1504–1508.
- [9] K. Folkers, R. Brown, W.V. Judy, and M. Morita, *Survival of cancer patients on therapy with coenzyme Q10*, Biochem. Biophys. Res. Comm. 192 (1993), pp. 241–245.
- [10] R.T. Matthews, L. Yang, S. Browne, M. Baik, and M.F. Beal, *Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effect*, Proc. Natl Acad. Sci. USA 95 (1998), pp. 8892–8897.
- [11] C.W. Shults, D. Oakes, K. Kieburtz, M.F. Beal, R. Haas, S. Plumb, J.L. Juncos, J. Nutt, I. Shoulson, J. Carter, K. Kompoliti, J.S. Perlmutter, S. Reich, M. Stern, R.L. Watts, R. Kurlan, E. Molho, M. Harrison, M. Lew, and Parkinson Study Group, *Effects of coenzyme Q10 in early Parkinson disease. Evidence of slowing of the functional decline*, Arch. Neurol. 59 (2002), pp. 1541–1550.
- [12] A.M. Sojka and S.A. Mortensen, *Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials*, Molec. Aspects Med. 18 (1997), pp. 159–168.
- [13] M.T. Tran, T.M. Mitchell, D.T. Kennedy, and J.T. Giles, *Role of coenzyme Q10 in chronic heart failure, angina, and hypertension*, Pharmacotherapy 21 (2001), pp. 797–806.
- [14] B. Frei, M.C. Kim, and B.N. Ames, *Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations*, Proc. Natl Acad. Sci. USA 87 (1990), pp. 4879–4883.
- [15] A.M. James, R.A.J. Smith, and M.P. Murphy, *Antioxidant and prooxidant properties of mitochondrial coenzyme Q*, Arch. Biochem. Biophys. 423 (2004), pp. 47–56.
- [16] Y. Yamamoto and S. Yamashita, *Plasma ratio of ubiquinol and ubiquinone as a marker of oxidative stress*, Molec. Aspects Med. 18 (1997), pp. 79–84.
- [17] T. Menke, P. Niklowitz, S. Adam, M. Weber, B. Schluter, and W. Andler, *Simultaneous detection of ubiquinol-10, ubiquinone-10, and tocopherols in human plasma microsomes and macrosamples as a marker of oxidative damage in neonates and infants*, Anal. Biochem. 282 (2000), pp. 209–217.
- [18] M.R. Moncelli, R. Herrero, L. Becucci, and R. Guidelli, *Kinetics of electron and proton transfer to ubiquinone-10 and from ubiquinol-10 in a self-assembled phosphatidylcholine monolayer*, Biochim. Biophys. Acta 1364 (1998), pp. 373–384.
- [19] T. Takahashi, T. Okamoto, K. Mori, H. Sayo, and T. Kishi, *Distribution of ubiquinone and ubiquinol homologues in rat tissues and subcellular fractions*, Lipids 28 (1993), pp. 803–809.
- [20] J. Abramson, S. Riistama, G. Larsson, A. Jasaitis, M. Svensson-Ek, L. Laakkonen, A. Puustinen, S. Iwata, and M. Wikström, *The structure of the ubiquinol oxidase from Escherichia coli and its ubiquinone binding site*, Nat. Struct. Biol. 7 (2000), pp. 910–917.
- [21] R. Covian and B.L. Trumpower, *Regulatory interactions between ubiquinol oxidation and ubiquinone reduction sites in the dimeric cytochrome bc<sub>1</sub> complex*, J. Biol. Chem. 281 (2006), pp. 30925–30932.
- [22] J.A. Nilsson, A. Lyubartsev, L.A. Eriksson, and A. Laaksonen, *Molecular dynamics simulations of ubiquinone: a survey over torsional potentials and hydrogen bonds*, Molec. Phys. 99 (2001), pp. 1795–1804.
- [23] J.A. Söderhäll and A. Laaksonen, *Molecular dynamics simulations of ubiquinone inside a lipid bilayer*, J. Phys. Chem. B 105 (2001), pp. 9308–9315.
- [24] S. Miyamoto, A. Kawai, S. Higuchi, Y. Nishi, T. Tanimoto, Y. Uekaji, D. Nakata, H. Fukumi, and K. Terao, *Structural studies of coenzyme Q10 inclusion complex with  $\gamma$ -cyclodextrin using chemical analyses and molecular modeling*, Chem-Bio. Infor. J. 9 (2009), pp. 1–11.
- [25] D. van der Spoel, E. Lindahl, B. Hess, A.R. van Buuren, E. Apol, P.J. Meulenhoff, D.P. Tieleman, A.L.T.M. Sijbers, K.A. Feenstra, R. van Drunen, and H.J.C. Berendsen, *GROMACS user manual version 3.3*. Available at <http://www.gromacs.org>, The Netherlands, 2004.
- [26] A.W. Schuettelkopf and D.M.F. van Aalten, *PRODRG: A tool for high-throughput crystallography of protein–ligand complexes*, Acta Crystallogr. D Biol. Crystallogr. 60 (2004), pp. 1355–1363.
- [27] W.F. van Gunsteren, S.R. Billeter, A.A. Eising, P.H. Hunenberger, P. Kruger, A.E. Mark, W.R.P. Scott, and I.G. Tironi, *Biomolecular Simulation: The GROMOS96 Manual and User Guide*, vdf

- Hochschulverlag AG an der ETH Zurich and BIOMOS b.v., Zurich, 1996.
- [28] H.J.C. Berendsen, J.P.M. Postma, W.F. van Gunsteren, and J. Herman, *Interaction models for water in relation to protein hydration*, in *Intermolecular Forces*, B. Pullman, ed., Reidel Publishing Company, Dordrecht, 1981, pp. 331–342.
  - [29] H.J.C. Berendsen, J.P.M. Postma, A.D. Nola, and J.R. Haak, *Molecular dynamics with coupling to an external bath*, J. Chem. Phys. 81 (1984), pp. 3684–3690.
  - [30] B. Hess, H. Bekker, H.J.C. Berendsen, and J.G.E.M. Fraaije, *LINCS: A linear constraint solver for molecular simulations*, J. Comput. Chem. 18 (1997), pp. 1463–1472.
  - [31] T. Darden, D. York, and L. Pedersen, *Particle Mesh Ewald: An  $N - \log(N)$  method for Ewald sums in large systems*, J. Chem. Phys. 98 (1993), pp. 10089–10092.
  - [32] R.W. Hockney, *The potential calculation and some applications*, Methods Comput. Phys. 9 (1970), pp. 136–211.
  - [33] W. Humphrey, A. Dalke, and K. Schulten, *VMD – visual molecular dynamic*, J. Mol. Graphics 14 (1996), pp. 33–38.
  - [34] U. Burkert and N.L. Allinger, *Molecular Mechanics*, ACS Monograph 177, American Chemical Society, Washington, DC, 1982.
  - [35] N.L. Allinger, *Conformational analysis. 130. MM2. A hydrocarbon force field utilizing V1 and V2 torsional terms*, J. Am. Chem. Soc. 99 (1977), pp. 8127–8134.
  - [36] J.J.P. Stewart, *Optimization of parameters for semi-empirical methods I-method*, J. Comput. Chem. 10 (1989), pp. 209–220.
  - [37] C.C.J. Roothaan, *New developments in molecular orbital theory*, Rev. Mod. Phys. 23 (1951), pp. 69–89.
  - [38] P. Fletcher, *Practical Methods of Optimization*, Wiley, Cornwall, UK, 1990.
  - [39] W.V. Judy, W.W. Stogsdill, D.S. Judy, and J.S. Judy, *Coenzyme Q10 Facts or Fabrications*, Natural Products Insider, Virgo Publishing, 22 October 2007.
  - [40] A. Maroz, R.F. Anderson, R.A.J. Smith, and M.P. Murphy, *Reactivity of UQ and ubiquinol with superoxide and the hydroperoxyl radical: Implications for in vivo antioxidant activity*, Free Radic. Biol. Med. 46 (2009), pp. 105–109.